Review



pan t cell negative selection kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Miltenyi Biotec pan t cell negative selection kit
    Pan T Cell Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 2794 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Pan+T+Cell+Isolation+Kit%2C+human/pmc13336833-111-10-16
    Average 97 stars, based on 2794 article reviews
    pan t cell negative selection kit - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Isolation:

    Article Title: INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis
    Article Snippet: .. Primary T cells were isolated from PBMCs via negative selection using the Pan T Cell Isolation Kit (Miltenyi Biotec). .. Purified T cells were activated with Human T-Activator CD3/CD28 Dynabeads (Gibco) at a bead-to-cell ratio of 1:1 in X-VIVO 15 medium (Lonza) supplemented with 5% human AB serum (Sigma-Aldrich) and recombinant human IL-2 (100 IU/mL, PeproTech).

    Article Title: Single-allele nanoscale mapping of regulatory variants
    Article Snippet: .. The peripheral blood mononuclear cell layer was isolated and CD4 + or CD3 + pan-T cells were enriched with CD4 + magnetic beads (Miltenyi, cat. no. 130-045-101) or pan-T cell isolation kit (Miltenyi, cat. no. 130-096-535), respectively, as per the manufacturer’s instructions. .. CD4 + or CD3 + cells were cultured at 1 × 10 6 cells ml −1 in Immunocult-XF T cell expansion medium (STEMCELL Technologies, cat. no. 10981) supplemented with 25 μl ml −1 of Immunocult Human CD3, CD28, CD2 T cell activator (STEMCELL Technologies, cat. no. 100-0785) and 10 ng ml −1 of human interleukin-2 (Invitrogen), for 60 h, before collection.

    Article Title: Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma
    Article Snippet: .. Pan T cells were isolated from PBMCs by negative selection using the human Pan T Cell Isolation Kit (Miltenyi Biotec, catalog #130-096-535) according to the manufacturer's instructions. ..

    Article Title: CTLA4 rs3087243-A-linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells.
    Article Snippet: The data was analyzed with the FlowJo software (v.10.8.1, BD). .. All flow cytometry assays and analyses were performed in accordance with the published “Guidelines for the use of flow cytometry and cell sorting in immunological studies.”37 CTLA-4 expression after T-cell stimulation CD3+ T cells were isolated from thawed PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec, #130-096-535) according to the manufacturer’s protocol and rested overnight at +37 �C (5% CO2) in supplemented RPMI + 5% human AB serum (RPMI-AB; Table S6). .. After resting, T cells were transferred to 2 separate flat-bottom 96-well Nuclon Delta plates (Thermo Scientific, #168055) in aliquots of 2.5 × 105 T cells in 250 μL RPMI-AB.

    Selection:

    Article Title: INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis
    Article Snippet: .. Primary T cells were isolated from PBMCs via negative selection using the Pan T Cell Isolation Kit (Miltenyi Biotec). .. Purified T cells were activated with Human T-Activator CD3/CD28 Dynabeads (Gibco) at a bead-to-cell ratio of 1:1 in X-VIVO 15 medium (Lonza) supplemented with 5% human AB serum (Sigma-Aldrich) and recombinant human IL-2 (100 IU/mL, PeproTech).

    Article Title: Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma
    Article Snippet: .. Pan T cells were isolated from PBMCs by negative selection using the human Pan T Cell Isolation Kit (Miltenyi Biotec, catalog #130-096-535) according to the manufacturer's instructions. ..

    Cell Isolation:

    Article Title: INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis
    Article Snippet: .. Primary T cells were isolated from PBMCs via negative selection using the Pan T Cell Isolation Kit (Miltenyi Biotec). .. Purified T cells were activated with Human T-Activator CD3/CD28 Dynabeads (Gibco) at a bead-to-cell ratio of 1:1 in X-VIVO 15 medium (Lonza) supplemented with 5% human AB serum (Sigma-Aldrich) and recombinant human IL-2 (100 IU/mL, PeproTech).

    Article Title: Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma.
    Article Snippet: .. The study was designed as an exploratory proof-of-concept investigation and sample sizes were selected based on feasibility, ethical considerations, and previous experience with this orthotopic model. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD19 antibody clone OTI3B10 Origene Cat# TA506236; RRID: AB_3096402 CD19 CAR detection reagent Miltenyi Biotec Cat# 130–115–965; RRID: AB_2811310 Biological samples Human PBMC leukapheresis cones Etablissement Français du Sang (EFS), France N/A Experimental models: cell lines TK-Luc human brain lymphoma cells Rudy Birsen team, Institut Cochin, Paris, France N/A Experimental models: organisms/strains RRGS rats (Rag2− /− Il2Rγ− /− expressing human SIRPα) Ménoret et al. (ref. 28) N/A Chemicals, peptides, and recombinant proteins Pan T cell Isolation Kit, human Miltenyi Biotec Cat# 130–096–535; RRID: AB_3695577 anti-CD3/CD28 Dynabeads Thermo Fisher Scientific Cat# 11131D; RRID: AB_2916088 CryoStor CS10 STEMCELL Technologies Cat# 07930; RRID: N/A Software and algorithms GraphPad Prism GraphPad Software Version 10.3.0 Living Image PerkinElmer Version 4.5.2 Other IVIS Spectrum PerkinElmer N/A Small Animal Radiation Research Platform (SARRP) Xstrahl N/A AxioZoom V16 microscope Zeiss N/A Public data repository Figshare https://doi.org/10.6084/m9.figshare. ..

    Article Title: Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity
    Article Snippet: Human Th1/Th2 Cytokine Kit II (CBA) , BD , Cat# 551809. .. Pan T cell Isolation Kit , Miltenyi Biotec , Cat# 130–096-535. .. TransAct , Miltenyi Biotec , Cat# 130–111-160.

    Article Title: LC3-associated phagocytosis is impaired in monocyte-derived macrophages from systemic sclerosis patients
    Article Snippet: Accutase , – , Gibco, A1110501. .. Pan T cell Isolation Kit, human , – , Miltenyi Biotec, 130-096-535. .. CD14 MicroBeads, human , 20 μL/10 7 cells , Miltenyi Biotec, 130-050-201.

    Article Title: The Mitochondria-Modulating Small Molecule TEM1657 Suppresses NFKBIZ Pathway and Resolves Th17-Driven Psoriatic Inflammation
    Article Snippet: .. T cells were obtained from the PBMCs of a healthy donor using Pan T cell isolation kit (Miltenyi, ref. 130-096-535) by following the manufacturer’s protocol. ..

    Article Title: Single-allele nanoscale mapping of regulatory variants
    Article Snippet: .. The peripheral blood mononuclear cell layer was isolated and CD4 + or CD3 + pan-T cells were enriched with CD4 + magnetic beads (Miltenyi, cat. no. 130-045-101) or pan-T cell isolation kit (Miltenyi, cat. no. 130-096-535), respectively, as per the manufacturer’s instructions. .. CD4 + or CD3 + cells were cultured at 1 × 10 6 cells ml −1 in Immunocult-XF T cell expansion medium (STEMCELL Technologies, cat. no. 10981) supplemented with 25 μl ml −1 of Immunocult Human CD3, CD28, CD2 T cell activator (STEMCELL Technologies, cat. no. 100-0785) and 10 ng ml −1 of human interleukin-2 (Invitrogen), for 60 h, before collection.

    Article Title: Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma
    Article Snippet: .. Pan T cells were isolated from PBMCs by negative selection using the human Pan T Cell Isolation Kit (Miltenyi Biotec, catalog #130-096-535) according to the manufacturer's instructions. ..

    Expressing:

    Article Title: Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma.
    Article Snippet: .. The study was designed as an exploratory proof-of-concept investigation and sample sizes were selected based on feasibility, ethical considerations, and previous experience with this orthotopic model. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD19 antibody clone OTI3B10 Origene Cat# TA506236; RRID: AB_3096402 CD19 CAR detection reagent Miltenyi Biotec Cat# 130–115–965; RRID: AB_2811310 Biological samples Human PBMC leukapheresis cones Etablissement Français du Sang (EFS), France N/A Experimental models: cell lines TK-Luc human brain lymphoma cells Rudy Birsen team, Institut Cochin, Paris, France N/A Experimental models: organisms/strains RRGS rats (Rag2− /− Il2Rγ− /− expressing human SIRPα) Ménoret et al. (ref. 28) N/A Chemicals, peptides, and recombinant proteins Pan T cell Isolation Kit, human Miltenyi Biotec Cat# 130–096–535; RRID: AB_3695577 anti-CD3/CD28 Dynabeads Thermo Fisher Scientific Cat# 11131D; RRID: AB_2916088 CryoStor CS10 STEMCELL Technologies Cat# 07930; RRID: N/A Software and algorithms GraphPad Prism GraphPad Software Version 10.3.0 Living Image PerkinElmer Version 4.5.2 Other IVIS Spectrum PerkinElmer N/A Small Animal Radiation Research Platform (SARRP) Xstrahl N/A AxioZoom V16 microscope Zeiss N/A Public data repository Figshare https://doi.org/10.6084/m9.figshare. ..

    Article Title: CTLA4 rs3087243-A-linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells.
    Article Snippet: The data was analyzed with the FlowJo software (v.10.8.1, BD). .. All flow cytometry assays and analyses were performed in accordance with the published “Guidelines for the use of flow cytometry and cell sorting in immunological studies.”37 CTLA-4 expression after T-cell stimulation CD3+ T cells were isolated from thawed PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec, #130-096-535) according to the manufacturer’s protocol and rested overnight at +37 �C (5% CO2) in supplemented RPMI + 5% human AB serum (RPMI-AB; Table S6). .. After resting, T cells were transferred to 2 separate flat-bottom 96-well Nuclon Delta plates (Thermo Scientific, #168055) in aliquots of 2.5 × 105 T cells in 250 μL RPMI-AB.

    Recombinant:

    Article Title: Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma.
    Article Snippet: .. The study was designed as an exploratory proof-of-concept investigation and sample sizes were selected based on feasibility, ethical considerations, and previous experience with this orthotopic model. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD19 antibody clone OTI3B10 Origene Cat# TA506236; RRID: AB_3096402 CD19 CAR detection reagent Miltenyi Biotec Cat# 130–115–965; RRID: AB_2811310 Biological samples Human PBMC leukapheresis cones Etablissement Français du Sang (EFS), France N/A Experimental models: cell lines TK-Luc human brain lymphoma cells Rudy Birsen team, Institut Cochin, Paris, France N/A Experimental models: organisms/strains RRGS rats (Rag2− /− Il2Rγ− /− expressing human SIRPα) Ménoret et al. (ref. 28) N/A Chemicals, peptides, and recombinant proteins Pan T cell Isolation Kit, human Miltenyi Biotec Cat# 130–096–535; RRID: AB_3695577 anti-CD3/CD28 Dynabeads Thermo Fisher Scientific Cat# 11131D; RRID: AB_2916088 CryoStor CS10 STEMCELL Technologies Cat# 07930; RRID: N/A Software and algorithms GraphPad Prism GraphPad Software Version 10.3.0 Living Image PerkinElmer Version 4.5.2 Other IVIS Spectrum PerkinElmer N/A Small Animal Radiation Research Platform (SARRP) Xstrahl N/A AxioZoom V16 microscope Zeiss N/A Public data repository Figshare https://doi.org/10.6084/m9.figshare. ..

    Software:

    Article Title: Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma.
    Article Snippet: .. The study was designed as an exploratory proof-of-concept investigation and sample sizes were selected based on feasibility, ethical considerations, and previous experience with this orthotopic model. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD19 antibody clone OTI3B10 Origene Cat# TA506236; RRID: AB_3096402 CD19 CAR detection reagent Miltenyi Biotec Cat# 130–115–965; RRID: AB_2811310 Biological samples Human PBMC leukapheresis cones Etablissement Français du Sang (EFS), France N/A Experimental models: cell lines TK-Luc human brain lymphoma cells Rudy Birsen team, Institut Cochin, Paris, France N/A Experimental models: organisms/strains RRGS rats (Rag2− /− Il2Rγ− /− expressing human SIRPα) Ménoret et al. (ref. 28) N/A Chemicals, peptides, and recombinant proteins Pan T cell Isolation Kit, human Miltenyi Biotec Cat# 130–096–535; RRID: AB_3695577 anti-CD3/CD28 Dynabeads Thermo Fisher Scientific Cat# 11131D; RRID: AB_2916088 CryoStor CS10 STEMCELL Technologies Cat# 07930; RRID: N/A Software and algorithms GraphPad Prism GraphPad Software Version 10.3.0 Living Image PerkinElmer Version 4.5.2 Other IVIS Spectrum PerkinElmer N/A Small Animal Radiation Research Platform (SARRP) Xstrahl N/A AxioZoom V16 microscope Zeiss N/A Public data repository Figshare https://doi.org/10.6084/m9.figshare. ..

    Microscopy:

    Article Title: Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma.
    Article Snippet: .. The study was designed as an exploratory proof-of-concept investigation and sample sizes were selected based on feasibility, ethical considerations, and previous experience with this orthotopic model. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD19 antibody clone OTI3B10 Origene Cat# TA506236; RRID: AB_3096402 CD19 CAR detection reagent Miltenyi Biotec Cat# 130–115–965; RRID: AB_2811310 Biological samples Human PBMC leukapheresis cones Etablissement Français du Sang (EFS), France N/A Experimental models: cell lines TK-Luc human brain lymphoma cells Rudy Birsen team, Institut Cochin, Paris, France N/A Experimental models: organisms/strains RRGS rats (Rag2− /− Il2Rγ− /− expressing human SIRPα) Ménoret et al. (ref. 28) N/A Chemicals, peptides, and recombinant proteins Pan T cell Isolation Kit, human Miltenyi Biotec Cat# 130–096–535; RRID: AB_3695577 anti-CD3/CD28 Dynabeads Thermo Fisher Scientific Cat# 11131D; RRID: AB_2916088 CryoStor CS10 STEMCELL Technologies Cat# 07930; RRID: N/A Software and algorithms GraphPad Prism GraphPad Software Version 10.3.0 Living Image PerkinElmer Version 4.5.2 Other IVIS Spectrum PerkinElmer N/A Small Animal Radiation Research Platform (SARRP) Xstrahl N/A AxioZoom V16 microscope Zeiss N/A Public data repository Figshare https://doi.org/10.6084/m9.figshare. ..

    Magnetic Beads:

    Article Title: Single-allele nanoscale mapping of regulatory variants
    Article Snippet: .. The peripheral blood mononuclear cell layer was isolated and CD4 + or CD3 + pan-T cells were enriched with CD4 + magnetic beads (Miltenyi, cat. no. 130-045-101) or pan-T cell isolation kit (Miltenyi, cat. no. 130-096-535), respectively, as per the manufacturer’s instructions. .. CD4 + or CD3 + cells were cultured at 1 × 10 6 cells ml −1 in Immunocult-XF T cell expansion medium (STEMCELL Technologies, cat. no. 10981) supplemented with 25 μl ml −1 of Immunocult Human CD3, CD28, CD2 T cell activator (STEMCELL Technologies, cat. no. 100-0785) and 10 ng ml −1 of human interleukin-2 (Invitrogen), for 60 h, before collection.

    Flow Cytometry:

    Article Title: CTLA4 rs3087243-A-linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells.
    Article Snippet: The data was analyzed with the FlowJo software (v.10.8.1, BD). .. All flow cytometry assays and analyses were performed in accordance with the published “Guidelines for the use of flow cytometry and cell sorting in immunological studies.”37 CTLA-4 expression after T-cell stimulation CD3+ T cells were isolated from thawed PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec, #130-096-535) according to the manufacturer’s protocol and rested overnight at +37 �C (5% CO2) in supplemented RPMI + 5% human AB serum (RPMI-AB; Table S6). .. After resting, T cells were transferred to 2 separate flat-bottom 96-well Nuclon Delta plates (Thermo Scientific, #168055) in aliquots of 2.5 × 105 T cells in 250 μL RPMI-AB.

    FACS:

    Article Title: CTLA4 rs3087243-A-linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells.
    Article Snippet: The data was analyzed with the FlowJo software (v.10.8.1, BD). .. All flow cytometry assays and analyses were performed in accordance with the published “Guidelines for the use of flow cytometry and cell sorting in immunological studies.”37 CTLA-4 expression after T-cell stimulation CD3+ T cells were isolated from thawed PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec, #130-096-535) according to the manufacturer’s protocol and rested overnight at +37 �C (5% CO2) in supplemented RPMI + 5% human AB serum (RPMI-AB; Table S6). .. After resting, T cells were transferred to 2 separate flat-bottom 96-well Nuclon Delta plates (Thermo Scientific, #168055) in aliquots of 2.5 × 105 T cells in 250 μL RPMI-AB.

    Cell Stimulation:

    Article Title: CTLA4 rs3087243-A-linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells.
    Article Snippet: The data was analyzed with the FlowJo software (v.10.8.1, BD). .. All flow cytometry assays and analyses were performed in accordance with the published “Guidelines for the use of flow cytometry and cell sorting in immunological studies.”37 CTLA-4 expression after T-cell stimulation CD3+ T cells were isolated from thawed PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec, #130-096-535) according to the manufacturer’s protocol and rested overnight at +37 �C (5% CO2) in supplemented RPMI + 5% human AB serum (RPMI-AB; Table S6). .. After resting, T cells were transferred to 2 separate flat-bottom 96-well Nuclon Delta plates (Thermo Scientific, #168055) in aliquots of 2.5 × 105 T cells in 250 μL RPMI-AB.



    Similar Products

    immunomagnetic separation kit  (MedChemExpress)
    94
    MedChemExpress immunomagnetic separation kit
    Immunomagnetic Separation Kit, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13458028-145-14-25
    Average 94 stars, based on 1 article reviews
    immunomagnetic separation kit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    human cd8 t cells  (MedChemExpress)
    94
    MedChemExpress human cd8 t cells
    Human Cd8 T Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pm42431878-333-13-28
    Average 94 stars, based on 1 article reviews
    human cd8 t cells - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    magnetic negative selection  (Miltenyi Biotec)
    96
    Miltenyi Biotec magnetic negative selection
    Magnetic Negative Selection, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Naive+CD4%2B+T+Cell+Isolation+Kit+II%2C+human/pmc13284711-33-11-21
    Average 96 stars, based on 1 article reviews
    magnetic negative selection - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    pan t cell negative selection kit  (Miltenyi Biotec)
    97
    Miltenyi Biotec pan t cell negative selection kit
    Pan T Cell Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Pan+T+Cell+Isolation+Kit%2C+human/pmc13336833-111-10-16
    Average 97 stars, based on 1 article reviews
    pan t cell negative selection kit - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    immunomagnetic negative selection  (Miltenyi Biotec)
    96
    Miltenyi Biotec immunomagnetic negative selection
    Immunomagnetic Negative Selection, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/B+Cell+Isolation+Kit%2C+mouse/pm42247288-209-25-29
    Average 96 stars, based on 1 article reviews
    immunomagnetic negative selection - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    immunomagnetic negative selection kit  (Miltenyi Biotec)
    95
    Miltenyi Biotec immunomagnetic negative selection kit
    Immunomagnetic Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Pan+B+Cell+Isolation+Kit%2C+mouse/pm42230556-305-13-24
    Average 95 stars, based on 1 article reviews
    immunomagnetic negative selection kit - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    human cd8 t cell negative selection  (MedChemExpress)
    94
    MedChemExpress human cd8 t cell negative selection
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .
    Human Cd8 T Cell Negative Selection, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13130659-81-0-8
    Average 94 stars, based on 1 article reviews
    human cd8 t cell negative selection - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    negative selection kit  (Miltenyi Biotec)
    97
    Miltenyi Biotec negative selection kit
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .
    Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/NK+Cell+Isolation+Kit%2C+human/pm42013130-259-8-11
    Average 97 stars, based on 1 article reviews
    negative selection kit - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    human cd8 t cell negative selection kit  (MedChemExpress)
    94
    MedChemExpress human cd8 t cell negative selection kit
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), <t>CD8</t> (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .
    Human Cd8 T Cell Negative Selection Kit, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13130659-446-11-19
    Average 94 stars, based on 1 article reviews
    human cd8 t cell negative selection kit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    negative selection macs separation kit  (Miltenyi Biotec)
    96
    Miltenyi Biotec negative selection macs separation kit
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), <t>CD8</t> (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .
    Negative Selection Macs Separation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/B+Cell+Isolation+Kit+II%2C+human/pmc13130636-396-6-11
    Average 96 stars, based on 1 article reviews
    negative selection macs separation kit - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Western Blot, Expressing, Control, Immunostaining, TUNEL Assay, Enzyme-linked Immunosorbent Assay

    mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Transwell Migration Assay, Labeling, Flow Cytometry, RNA Sequencing, Gene Expression, Biomarker Discovery, Expressing, Multiplex Assay, Cytokine Assay

    mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Flow Cytometry, Expressing, Immunofluorescence, Activation Assay

    Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Isolation, Expressing, Marker

    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Western Blot, Expressing, Control, Immunostaining, TUNEL Assay, Enzyme-linked Immunosorbent Assay

    mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Transwell Migration Assay, Labeling, Flow Cytometry, RNA Sequencing, Gene Expression, Biomarker Discovery, Expressing, Multiplex Assay, Cytokine Assay

    mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Flow Cytometry, Expressing, Immunofluorescence, Activation Assay

    Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Isolation, Expressing, Marker